Care-Tech Signs Consent Decree With FDA
The FDA has reported that Care-Tech Laboratories (Care-Tech) and its principal officers, John Brereton and Sherry Brereton, have signed a consent decree, agreeing to stop the illegal manufacture,
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
LigoCyte Pharmaceuticals (LigoCyte) has initiated its third human clinical trial of its norovirus vaccine. The phase I/II study will assess safety and immunogenicity associated with LigoCyte’s investigational, nasally-delivered,